Equity · Healthcare
AMLX
NASDAQAmylyx Pharmaceuticals (AMLX)
The line runs 20 USD on 3 August through 28.86 USD on 30 October, on a scale from 10 to 40. Days the market did not trade hold the previous close, flat.
- Market cap
- 3.2B USD
- Revenue, year to Dec 2025
- 0 USD
- EPS, diluted, year to Dec 2025
- −1.53 USD
- 52-week range
- 11 USD – 39.67 USD
- Avg volume
- 78.6K
as of Oct 30, 2026
Have Amylyx Pharmaceuticals (AMLX) insiders bought or sold shares recently?
In the 90 days to 1 Nov 2026, Amylyx Pharmaceuticals insiders reported 6 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 21 May 2026.
Form 4, 90 days to 1 Nov 2026, newest reported trade 5 Oct 2026
Buys 0Sells 6Net sold $3.78MOther filings 6
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 05 Oct 2026 | MILNE GEORGE M JRDirector | Sell | 30,000 | 831K USD |
| 10 Sep 2026 | Bedrosian Camille LChief Medical Officer | Sell | 10,028 | 325K USD |
| 10 Sep 2026 | FRATES JAMES MChief Financial Officer | Sell | 10,810 | 350K USD |
| 10 Sep 2026 | Mazzariello GinaChief Legal Officer | Sell | 9,536 | 310K USD |
| 10 Sep 2026 | Cohen Joshua BCo-Chief Executive Officer | Sell | 30,464 | 981K USD |
| 10 Sep 2026 | Klee Justin B.Co-Chief Executive Officer | Sell | 30,464 | 980K USD |
| Sold | 6 open-market sales | 121,302 | $3.78M |
6 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 31 Aug 2026 | Firestone KarenDirector | Option exercise | 50,000 | 170K USD |
| 18 Aug 2026 | FRATES JAMES MChief Financial Officer | Award | 22,807 | |
| 18 Aug 2026 | Klee Justin B.Co-Chief Executive Officer | Award | 60,039 | |
| 18 Aug 2026 | Mazzariello GinaChief Legal Officer | Award | 21,284 | |
| 18 Aug 2026 | Bedrosian Camille LChief Medical Officer | Award | 22,807 | |
| 18 Aug 2026 | Cohen Joshua BCo-Chief Executive Officer | Award | 60,039 |
Which funds hold Amylyx Pharmaceuticals (AMLX)?
6 of the 45 institutional funds we track reported a Amylyx Pharmaceuticals position for the quarter ended 30 Jun 2026 — a combined 30.3M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Balyasny Asset Management | Trimmed | 684,974 | 12.3M USD | −38.1% |
| Two Sigma Investments | Added | 593,435 | 10.7M USD | +266.4% |
| Citadel Advisors | Trimmed | 178,686 | 3.2M USD | −56.6% |
| D. E. Shaw & Co. | Added | 174,285 | 3.1M USD | +134.8% |
| Tudor Investment Corp | Held (±25%) | 35,410 | 636K USD | +13.0% |
| AQR Capital Management | Trimmed | 20,819 | 374K USD | −28.4% |
| Point72 Asset Management | Exited |
Have members of Congress traded Amylyx Pharmaceuticals (AMLX)?
The most recent congressional trade disclosed in Amylyx Pharmaceuticals is a purchase by Sara Jacobs (house, CA), dated 12 Oct 2022.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 12 Oct 2022 | Sara Jacobshouse · Democrat–CA | Purchase | 1K USD–15K USD | 35 days |
What has been filed or recorded for Amylyx Pharmaceuticals (AMLX)?
The filings we hold for Amylyx Pharmaceuticals, newest first: 1 fails-to-deliver day, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 21 Sep 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 21 Sep 2026 | Fails to deliver | Shares failed to deliver | 66 shares | 2K USD notional · <0.001% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.39 USD | |
| 30 Jun 2026 | Financials | Total assets | 264.6M USD | at period end |
| 30 Jun 2026 | Financials | Total equity | 239.2M USD | at period end |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.37 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −1.53 USD | |
| 31 Dec 2025 | Financials | Revenue | 0 USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −144.7M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −1.53 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.37 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.46 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.42 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −4.43 USD | |
| 30 Sep 2024 | Quarterly earnings | Q3 2024 reported | EPS −1.07 USD |
Amylyx Pharmaceuticals (AMLX): frequently asked questions
What did Amylyx Pharmaceuticals shares close at?
Amylyx Pharmaceuticals closed at 28.86 USD on 30 Oct 2026, up 0.61% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Amylyx Pharmaceuticals’ market cap?
Amylyx Pharmaceuticals is worth 3.2B USD by market value as of 30 Oct 2026, which is the share price times the shares on issue from its SEC filings.
What is Amylyx Pharmaceuticals’ revenue?
Amylyx Pharmaceuticals reported revenue of 0 USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Amylyx Pharmaceuticals insiders bought or sold shares recently?
In the 90 days to 1 Nov 2026, Amylyx Pharmaceuticals insiders reported 6 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 21 May 2026. A further 6 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Amylyx Pharmaceuticals?
6 of the 45 funds we track reported a Amylyx Pharmaceuticals position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Balyasny Asset Management, Two Sigma Investments and Citadel Advisors. See Funds
Have members of Congress traded Amylyx Pharmaceuticals?
Yes. 1 trade in Amylyx Pharmaceuticals appears in the congressional disclosures we hold: a purchase by Sara Jacobs (House, CA) dated 12 Oct 2022, filed 16 Nov 2022. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Amylyx Pharmaceuticals last report earnings?
Amylyx Pharmaceuticals last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −0.39 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings